medwireNews

Combining a GLP-1 receptor agonist or SGLT2 inhibitor with basal insulin allows people with type 2 diabetes on a basal–bolus regimen to drop the prandial insulin, shows the pragmatic BEYOND trial.

Previously untreated patients with advanced non-clear cell renal cell carcinoma could benefit from treatment with lenvatinib plus everolimus, suggests a phase 2 study.

A urate lowering treat-to-target approach combined with personalized advice can help the majority of patients with gout achieve satisfactory serum urate levels, but some modifiable barriers to target fulfillment still exist, Norwegian researchers report.

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

Routine vaccination rates are currently “inacceptable” among patients with chronic inflammatory rheumatic diseases in Germany, researchers report in RMD Open.

Combining metformin with a sulfonylurea produces poorer non-glycemic outcomes than combining it with other second-line agents, show results from the global DISCOVER program.